Bright Minds Biosciences DRUG 深 滬
等待開盤 11-26 09:30:00 美东时间
65.53
+5.060
+8.37%
華盛通- 最 高65.84
- 今 開60.77
- 成交量 9.15万股
- 最 低 59.01
- 昨 收 60.47
- 總市值 4.65亿
- 52周最高 70.23
- 市盈率 靜 --
- 換手率 1.29%
- 52周最低 23.175
- 委 比 60.00%
- 總股本 708.86万
- 歷史最高 79.02
- 量 比 0.60
- 振 幅 11.29%
- 歷史最低 0.93
- 每 手 1
- 風險率 10.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting
Bright Minds Biosciences will participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, and the 2025 American Epilepsy Society Annual Meeting on December 7, 2025. The company focuses on developing selective 5-HT2 agonists for treating epilepsy, depression, and CNS disorders, with a unique platform of serotonergic agonists.
11-25 21:30
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)
Bright Minds Biosciences has added four global experts in Prader-Willi Syndrome (PWS) to its Scientific Advisory Board to support its new PWS program. The company has initiated a clinical program focusing on BMB-101, a novel drug candidate aimed at addressing hyperphagia and behavioral symptoms of PWS. The program includes the NOVA clinical study, a Phase 2a trial designed to assess BMB-101's efficacy and safety. The experts' expertise will be in...
11-17 11:50
Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH
Bright Minds Biosciences announced the launch of its Prader-Willi Syndrome (PWS) program, including a Phase 2a NOVA study to evaluate BMB-101 for treating PWS symptoms and a Phase 1 study for BMB-105. The Company will hold a webcast on November 6 featuring experts discussing PWS treatment needs and clinical assessments. CEO Ian McDonald emphasized the potential of 5-HT₂C agonists to address PWS's underlying issues. BMB-101 has shown good safety a...
11-06 11:30
Bright Minds Biosciences to Present at Upcoming Conferences
Bright Minds Biosciences announced it will present at two upcoming conferences: the Guggenheim Healthcare Innovation Conference on November 12, 2025, and the Jefferies Global Healthcare Conference in London on November 10, 2025. Live and archived webcasts will be available for the Guggenheim event. The company also granted stock options to purchase 43,000 common shares under their share option plan.
10-30 22:30
瑞博生物治疗丁型肝炎病毒感染的小核酸药物RBD1016获EMA孤儿药资格认定
苏州瑞博生物技术股份有限公司(“瑞博生物”)及其子公司Ribocure Pharmaceuticals AB (“Ribocure”)共同宣布欧洲药品管理局(EMA)授予其小干扰RNA(siRNA)候选药物RBD1016孤儿药资格认定(Orphan Drug Designation, ODD)，用于治疗丁型肝炎病毒(HDV)的感染。
10-24 17:02
'Psychedelics Show Promise As An 'Entirely New Type Of Anti-Inflammatory Treatment,' Research Suggests' - Marijuana Moment
https://www.marijuanamoment.net/psychedelics-show-promise-as-an-entirely-new-type-of-anti-inflammatory-treatment-research-suggests/
10-14 01:28
Mark Cuban Says AI Race Explains Musk, Zuckerberg and Dell Support for Trump
Mark Cuban says that the backing of President Donald Trump by Big Tech is more about staying ahead in the AI race than political alignment.
09-28 03:11
Large Patient Population Is Key Driver For Bright Minds' Growth
BTIG initiates coverage on Bright Minds Biosciences with a Buy rating, citing BMB‑101's potential and key Phase 2 data expected by the end of 2025
09-09 01:54
BTIG Initiates Coverage On Bright Minds Biosciences with Buy Rating, Announces Price Target of $72
BTIG analyst Thomas Shrader initiates coverage on Bright Minds Biosciences (NASDAQ:DRUG) with a Buy rating and announces Price Target of $72.
09-08 18:10
'Military To Start Testing Service Members For The Psychedelic Psilocin, Memo Shows' - Marijuana Moment
https://www.marijuanamoment.net/military-to-start-testing-service-members-for-the-psychedelic-psilocin-memo-shows/
08-29 02:16
